The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Incyte’s JAK insurance policy heads for the clinic
A first-in-human trial of PRT12396 starts next month.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Cell therapies head for the clinic
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Pan-KRAS gets even more crowded
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
Henlius starts a pivotal journey to catch Pfizer
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
